Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adults aged 18 and over.
- Patients/Subjects able to give informed consent
- Patients/Subjects whose weight does not exceed 275 lbs.
- Patient with metastatic brain tumors greater than or equal to 1.0 cm that will be treated with stereotactic radiosurgery and scheduled for an MRI scan as part of their routine care
Exclusion Criteria:
- Patients who are unwilling or unable to undergo MRI including patients with contra-indications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Pts having an MRI
Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration.
Ten patients with brain metastasis will be recruited in the study.
All the patients will be undergoing SRS (Stereotactic Radiosurgery).
Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response.
Patients are to be administered contrast prior to obtaining MRI scans.
These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
feasibility of diffusion and perfusion magnetic resonance imaging (MRI)
Time Frame: 1 year
|
This is a technology assessment protocol for response to treatment.
The study is designed to assess the utility of the technology using a limited number of participants.
We will assess whether the MR parameters are predictive markers of early response.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kathryn Beal, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 13-094
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Cancer
-
NCT02045381CompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer Pelvis
-
NCT03721055UnknownCancer | Metastatic Cancer | Metastatic Brain Cancer
-
NCT02334722CompletedBrain Neoplasms | Brain Cancer | Brain Tumors | Seizure | Cancer of the Brain | Cancer of Brain
-
NCT00525590Completed
-
NCT07152782Not yet recruitingHER2-positive Breast Cancer | Breast Cancer With Brain Metastasis
-
NCT05170087Active, not recruitingBreast Cancer | Head and Neck Cancer | Gynecologic Cancer | Brain Cancer
-
NCT01473485Active, not recruitingGlioma | Metastatic Brain Cancer
-
NCT05087095CompletedBrain Metastases, Adult | Cancer Metastatic to Brain
-
NCT00610285Completed
Clinical Trials on MRI
-
NCT03940092Recruiting
-
NCT01880944Completed
-
NCT01882231TerminatedOsteosarcoma | Ewing Sarcoma | Paget's Disease
-
NCT03874208UnknownBrain Injury, Coma | Cardiac Arrest (CA) | Traumatic Brain Injury (TBI) | Aneurysmal Subarachnoid Hemorrhages (aSAH)
-
NCT02022579UnknownBreast Cancer | BIRADS 3 | BIRADS 4 | BIRADS 5
-
NCT04691011CompletedAmyotrophic Lateral Sclerosis
-
NCT03356366Active, not recruiting
-
NCT04649749CompletedBrachial Plexus Neuropathies | Traumatic Brachial Plexus Lesion | Bionic Hand Reconstruction